Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphoma
- 15 January 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (2) , 724-725
- https://doi.org/10.1182/blood.v99.2.724
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Prevalence of hepatitis B or C virus infections in patients with non‐Hodgkin's lymphomaJournal of Gastroenterology and Hepatology, 2001
- Lamivudine and Glycyrrhizin for Treatment of Chemotherapy-Induced Hepatitis B Virus (HBV) Hepatitis in a Chronic HBV Carrier with Non-Hodgkin LymphomaLeukemia & Lymphoma, 2001
- Long-term therapy of chronic hepatitis B with lamivudineHepatology, 2000
- Hepatitis B and C virus infection in Romanian non‐Hodgkin's lymphoma patientsBritish Journal of Haematology, 1999
- Chronic liver disease and lymphoproliferative disorders in HCV-positive patients: a working hypothesisJournal of Hepatology, 1998
- Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantationBone Marrow Transplantation, 1998
- High prevalence of hepatitis C virus infection in patients with B‐cell lymphoproliferative disorders in ItalyAmerican Journal of Hematology, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Hepatitis C virus infection in patients with non‐Hodgkin's lymphomaBritish Journal of Haematology, 1994
- Hepatitis B infection in patients with lymphomasHematological Oncology, 1990